Pharmaceuticals
OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration
LONDON, Oct. 7, 2026 /PRNewswire/ -- OncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical work with OB-001, demonstrating the product's potential to tackle two major unmet needs in oncology: ADC resistance and the brain pen...
2026-10-07 14:00
2177
XtalPi Debuts Kodexia™, the World's First Closed-Loop siRNA Platform Combining Generative AI with First-Principles Modeling
* This unified platform integrates sequence design, chemical modification, experimental validation, extrahepatic delivery design, and intellectual property strategy into an integrated computational–experimental workflow, pioneering in vivo efficacy prediction models to accelerate drug developme...
2026-10-06 22:42
4700
Hisun Pharmaceutical Celebrates 70th Anniversary with Global Partners at Milan-Taizhou Night
MILAN, Oct. 6, 2026 /PRNewswire/ -- Zhejiang Hisun Pharmaceutical Co., Ltd. hosted its 70th Anniversary Global Partners Appreciation Dinner in Milan on October 5, the eve of CPHI Milan 2026. Themed "Bridging Cultures, Advancing Health Together," the event brought together leading pharmaceutical c...
2026-10-06 21:32
1974
/C O R R E C T I O N -- Piramal Pharma Solutions/
In the news release, Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility, issued 06-Oct-2026 by Piramal Pharma Solutions over PR Newswire, we are advised by the company that changes have been made to the caption accompanying the first ima...
2026-10-06 16:59
3086
Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins
* Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026 * The trial provided initial safety and tolerability data for Lu AF28996, with most treatment-emergent adverse events reported as mild...
2026-10-06 14:35
3006
Dr. Oregonin Completes U.S. FDA Registration for OLTIS DENTAL-X, Unveiling Oral-Care Innovation Rooted in Trans-Pacific Alder Research
Botanical oral-care product bridges 1974 Oregon State University discovery of 'oregonin' with 27 years of natural-product research by South Korean scientists. SEOUL, South Korea, Oct. 6, 2026 /PRNewswire/ -- Dr. Oregonin Inc. today announced that it has completed U.S. Food and Drug Administration...
2026-10-06 13:50
2374
Docquity Extends Asian Healthcare Intelligence to Japan Through Deepened Strategic Partnership with exMedio
Japan scale up advances Docquity's goal of Asian Healthcare Intelligence built on Clinical Intent, with Ask Dx as the core platform and "One Asia" linking physicians in Japan and Southeast Asia SINGAPORE, Oct. 6, 2026 /PRNewswire/ -- Docquity, the clinical AI platform for more than 75% of verifi...
2026-10-06 11:51
2395
OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.
* OMLYCLO® (omalizumab-igec) is the first and onlyFDA-approved omalizumab biosimilar approved for all four indications of XOLAIR® (omalizumab) and designated as interchangeable with XOLAIR; OMLYCLO® will be available in 75 mg/0.5 mL, 150 mg/mL and 300mg/2mL in a single-dose prefilled syringe fo...
2026-10-05 20:45
3429
Ajinomoto Bio-Pharma Services Unveils Refreshed Global Brand, Showcasing its Strength in Specialization
* Reflects the depth of expertise and innovation Aji Bio-Pharma brings to customers navigating increasingly demanding development and manufacturing challenges TOKYO, Oct. 5, 2026 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a global network of specialized contract developme...
2026-10-05 19:00
4481
Energenesis Biomedical and Yoo Young Pharm Sign MOU for ENERGI-F703DFU Development and Commercialization in Korea
TAIPEI, Oct. 5, 2026 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657) today announced that it has signed a Memorandum of Understanding ("MOU") with Yoo Young Pharm. Co., Ltd. ("YYP"), a South Korea-based pharmaceutical company, to explore a collaboration for the development, registra...
2026-10-05 18:00
2560
Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers
Published multicenter study found higher complete wound closure rates and faster healing with Symphony plus standard of care AUCKLAND, New Zealand, Oct. 5, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today announced positive results from a prospec...
2026-10-05 12:46
2490
AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)
The only known investigational therapy for SBMA in Phase 3 development worldwide * AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBMA, or Kennedy's disease) * Following submission of the Ph...
2026-10-05 12:30
2681
Celaid Therapeutics Completes Second Close of Series B Financing Round
Shionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate U.S. Clinical Trial Preparations for CLD-001 TOKYO, Oct. 4, 2026 /PRNewswire/ -- Celaid Therapeutics Inc. (Head Office: Bunkyo-ku, Tokyo, Japan; President and CEO: Nobuyuki Arakawa; "Celaid") today announced the complet...
2026-10-05 09:30
1870
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 5, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global collab...
2026-10-05 05:46
3857
SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026
MILAN, Oct. 4, 2026 /PRNewswire/ -- At the European Association for the Study of Diabetes (EASD) 2026, SiBionics presented "See More, Act Earlier," connecting continuous sensing with future diabetes care. Three exhibition chapters shaped this vision: "See More: Beyond Glucose," covering glucose, ...
2026-10-04 10:47
2869
Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy
* First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a monogenic disease. * Paired muscle biopsies reveal 3.5- to 5.3-fold increases in sarcolemmal utrophin expression,...
2026-10-03 19:30
6517
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026
SHANGHAI and HONG KONG, Oct. 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dise...
2026-10-03 08:30
10313
/DISREGARD RELEASE: Jiangsu Vcare/
We are advised by Jiangsu Vcare that journalists and other readers should disregard the news release, Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA, issued 04-Jan-2024 over PR Newswire. ...
2026-10-02 19:12
4917
Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026
HONG KONG, Oct. 2, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced the presentation of key preclinical data for its ASC36_35FDC (ASC36_35 co-formulation) at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, being held September 28–Oc...
2026-10-02 17:00
3689
Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026
* Late-breaking Phase III MASCOT oral presentation will characterize the clinical profile and diversity of participants in Lundbeck's ongoing global Phase III trial investigating amlenetug in multiple system atrophy (MSA) * New research across clinical trial endpoints, biomarkers, diagnostic t...
2026-10-02 15:05
3680
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21CHANDO Group Presents 20 Research Papers at IFSCC 2026 Congress in Perth
[Picked up by 260 media titles]
2026-10-06 11:40
Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
9459
DayOne Files Registration Statement for Proposed Initial Public Offering
2026-10-06 05:28
9058
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8596
